Background: Since publication of the UK Prospective Diabetes Study (UKPDS) in 1998, there has been a clear evidence base for tight glycaemic (HBA 1c < 7.0%) and blood pressure (BP < 140/ 85 mmHg) control. Aim: To determine the effect of UKPDS-based intensified glycaemic and BP targets on the care of type 2 diabetic patients attending a routine diabetes clinic. Design: Two surveys, each of 500 consecutively attending type 2 diabetic patients. Methods: The first survey was in a 3-month period in 1999, shortly after publication of the UKPDS study. The second was identical, but 2 years later. Glycaemic control (by DCCT-aligned HBA 1c ), BP and treatment details were recorded in both.
Introduction
Type 2 diabetes is associated with a high risk of cardiovascular mortality and morbidity, accounting for almost two-thirds of all deaths in diabetic patients, with up to 75% of cardiovascular disease in diabetic subjects being attributed to hypertension. [1] [2] [3] Tight glycaemic and blood pressure (BP) control reduces the risk of microvascular and macrovascular complications. 4, 5 International management guidelines have been developed to help achieve targets 6 and improve cardiovascular status, but attaining such standards in type 2 diabetes is difficult. Evidence from the UK Prospective Diabetes Study (UKPDS) 4, 5 has been used to set targets for glycaemic (HbA 1c ) and BP control that are associated with significantly reduced mortality and morbidity. Since this study reported in 1998, diabetic clinics have been greatly increasing efforts to intensify glycaemic and BP control, but it remains uncertain how effective such efforts have been. 7 We report two detailed assessments of HbA 1c and BP control in a large number of type 2 patients attending our clinic-the first in 1999 8 just after publication of the UKPDS, and the second 2 years later in 2001.
Methods
The Walton Diabetes Centre at the University Hospital Aintree provides specialist diabetic care for the population of north Liverpool, UK. The Diabetes Centre caseload of more than 5000 patients includes patients with type 1 and type 2 diabetes, many with complex problems. For the purpose of this study, we defined type 2 diabetes as any person developing the disease after the age of 30 years, and not requiring insulin at diagnosis. Patients within one year of diagnosis were excluded from the study.
The initial audit of 500 type 2 patients attending the Diabetes Centre follow-up clinics during a 3-month period in 1999, was done by consecutive case-note extraction onto proforma, and has been reported previously. 8 At the time of the second audit (2 years later), hospital and out-patient activity was computerized, and we used data extraction of consecutive type 2 patients attending clinics during a similar 3-month period in 2001.
Our criteria for 'control' of HbA 1c and BP levels were based on UKPDS data. 4, 5 HbA 1c was measured by high pressure liquid chromatography (HPLC). The assay was aligned to the Diabetes Control and Complications Trial 9 ('DCCT aligned'), and was identical in both studies. An HbA 1c level < 7.0% was regarded as good control and > 8.0% as poor control. BP was also measured by the same method in both studies with a Dynamap Compact T monitor. A BP level < 140/85 was used to define 'controlled' BP, and above this level for 'uncontrolled' BP. Unlike HbA 1c levels, however, BP levels were highly significantly improved between 1999 and 2001. This included analysis of systolic and diastolic BP, proportion of patients with uncontrolled hypertension (BP > 140/85), and proportion of patients on antihypertensive treatment (Table 3) . Multiple drug treatment was also more common, and in 2001 only 17% of patients with a BP level > 140/85 were not on antihypertensive medication, compared with 45% in 1999 (p < 0.0001).
Discussion
This study describes and compares two separate audits of type 2 diabetic patients attending a single diabetic clinic, 2 years apart. A possible limitation of the study is that patient cohorts were different at the two study times. However, the numbers were large and the groups well-matched. In fact, there are also significant problems in assessing treatment efficacy in the same type 2 diabetic patients sequentially over time, as the UKPDS study has clearly shown that glycaemic control deteriorates significantly as diabetes duration prolongs.
4,10 Even a 2-year excess in diabetes duration would therefore mean that glycaemic control could not be validly compared.
The striking finding of this study is that we were able to 'close the audit loop' and greatly improve the shortfalls in hypertensive control. Mean BP fell highly significantly from 151/77 in 1999 to 146/72 in 2001. There was clearly more liberal use of antihypertensive drugs, the proportion of hypertensive patients on drugs almost doubling from 33% to 60% (p < 0.0001). This change in treatment philosophy was probably driven by the remarkable outcome improvements in strict BP control reported in the UKPDS, 5 and we believe that a general 'BP awareness' amongst clinic doctors was the major factor driving these dramatic improvements. We did not evaluate complication prevalence in the two groups, but have no reason to believe that rates were significantly different, or that this may have affected treatment practices. In our clinic we have always aimed to treat patients to current evidence-based targets, regardless of co-morbidity or complications.
In contrast, our findings on glycaemic control are less encouraging. Mean HbA 1c was unchanged at 8.7% in 1999 and 8.5% in 2001. However, there was evidence that the case-mix of patients had changed. The population on diet-only decreased from 27% to 12%, those on oral agents increased from 59% to 68% and those on insulin increased from 14% to 20%. This was partly due to increased use of oral agents and insulin, but also to a clinic policy of discharging stable dietcontrolled patients to community care. Thus, the 2001 cohort may represent a more problematic group. Nevertheless, it remains of concern that over half of patients in both studies (58% in 1999 and 56% in 2001) undoubtedly had poor glycaemic control (HbA 1c > 8.0%). Interestingly, a recent Danish intervention study in type 2 diabetes has shown that even with intensive management, target HbA 1c levels are hard to achieve in significant numbers of patients. 11 As with our findings, BP targets were more attainable. Numbers are those with BP levels recorded in the last 12 months (< 500 because of patients who had missed appointments and not had BP measurements in the previous 12 months).
In conclusion, our study shows that hypertension control can be significantly improved in type 2 diabetic patients within the structure of routine hospital clinic care. Achieving glycaemic targets, however, appears to remain a 'holy grail', so far unobtainable.
